Abstract 122P
Background
This study aims to evaluate the effectiveness of using Pembrolizumab or Sintilimab combined with chemotherapy in NSCLC treatment using the Propensity Score Matching (PSM) analysis.
Methods
The NSCLC patients were treated with neoadjuvent Pembrolizumab or Sintilimab combined with chemotherapy in two hospitals since June 2018. The objective response rate (ORR), pathological complete response (pCR), and operation-related information of the two groups were analyzed by PSM analysis.
Results
Here, 116 patients were enrolled in the study, where 61 were classified into the Sintilimab group while 55 were included in the Pembrolizumab group. The results indicated that 28 patients (45.9%) in the Sintilimab group achieved pCR while 30 patients (54.5%) in the Pembrolizumab group showed pCR(P = 0.353). No significant differences were noted in MPR between the Sintilimab and Pembrolizumab groups (39, 63.9% vs 36, 65.5%, P = 0.861). Furthermore, the ORR values showed no statistically significant differences between the groups when compared to the assessment of the effects by the Sintilimab and the Pembrolizumab groups (46, 75.4% vs. 44, 80.0%, P = 0.554). There was no discernible difference in ORR and pCR values between the two groups after the first and second PSM analyses. After a Logistic analysis, before and after PSM, treatment with ≥3 cycles were still regarded as the promoting factor of pCR.
Table: 122P| Sintilimab (n = 61) | Pembrolizumab(n = 55) | P | |
|---|---|---|---|
| Sex | 0.493 | ||
| Male | 53(86.9) | 50(90.9) | |
| Female | 8(13.1) | 5(9.1) | |
| Age | 0.864 | ||
| ≥60 | 39(63.9) | 36(65.5) | |
| <60 | 22(36.1) | 19(34.5) | |
| BMI | 0.001 | ||
| ≥24 | 12(19.7) | 26(47.3) | |
| <24 | 49(80.3) | 29(52.7) | |
| Smoking Index | 0.07 | ||
| ≥400 | 48(78.7) | 40(72.7) | |
| <400 | 13(21.3) | 15(27.3) | |
| Pathological type | 0.069 | ||
| Squamous cell cancer | 45(73.8) | 48(87.3) | |
| Adenocarcinoma Cycles of neoadjuvant therapy | 16(26.2) | 79(12.7) | 0.002 |
| ≤2 | 30(49.2) | 12(21.8) | |
| ≥3 | 31(50.8) | 43(78.2) | |
| Clinical stage | 0.670 | ||
| I, II | 14(22.9) | 11(20.0) | |
| III | 47(77.1) | 44(80.0) | |
| RECIST 1.1 evaluation | 0.554 | ||
| ORR | 46(75.4) | 44(80.0) | |
| NON-ORR | 15(25.6) | 11(20.0) | |
| Pathlogical evaluation | 0.353 | ||
| pCR | 28(45.9) | 30(54.5) | |
| NON-pCR | 33(54.1) | 25(45.5) |
Conclusions
Sintilimab or Pembrolizumab combined with chemotherapy display a similar pCR to the neoadjuvant treatment of resectable NSCLC. So these both PD-1 inhibitors could show similar effects in NSCLC treatment.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.